Aptamer Sciences Inc (KOSDAQ:291650)

South Korea · Delayed Price · Currency is KRW

950.00

+98.00 (11.50%)

At close: Jul 21, 2026

-23.51% (1Y)

Market Cap	57.99B +59.5%
Revenue (ttm)	n/a +281.6%
Net Income	n/a
EPS	n/a
Shares Out	61.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,124
Open	877.00
Previous Close	852.00
Day's Range	835.00 - 950.00
52-Week Range	675.00 - 1,998.00
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Aptamer Sciences

Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2011

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 291650

Full Company Profile

Financial Performance

In 2024, Aptamer Sciences's revenue was 1.08 billion, an increase of 345.26% compared to the previous year's 243.19 million. Losses were -8.70 billion, -36.02% less than in 2023.

Financial Statements